Skip to main content
. 2018 Jun 22;9(8):241–254. doi: 10.1177/2042018818781414

Table 2.

General characteristics of included studies.

Study Year
of publication		 Type
of study		 Number
of participants* 		Male (%) Mean
age		 Patients Location
of study		 Scope Conflict of interest Financing Classification of the duration of the study**** Total score in Newcastle–Ottawa Scale
Abali et al. 29 2014 Cohort no (concurrent) 117
(85/32)		 55 12 ± 3.4 Pediatric Turkey SC NR NR Long 7
Haukka et al. 30 2013 Cohort no (concurrent) 7110 (3359/7110) NR NR Pediatric and adult Finland MC Yes Novo Nordisk Long 6
Kabadi et al. 31 2008 Cohort no (concurrent) 45
(24/21)		 56 NR Adult USA SC No No Intermediate 7
Jinno et al. 32 2012 Cohort no concurrent 90
(29/90)		 36 11.9 ± 3.8 Pediatric Japan MC NR Japan Diabetes Foundation Long 6
Hermansen et al. 33 2009 Cohort no (concurrent) 643
(643/643)		 39 40.3 ±15.7 Adult 6 countries ** MC Yes Novo Nordisk Intermediate 7
Preumont et al. 34 2009 Cohort no (concurrent) 181
(181/181)		 NR NR Adult Belgium SC Yes Novo Nordisk Intermediate 6
Yenigun et al. 35 2009 Cohort no
(concurrent)		 508
(482/26)		 48 NR Adult 11 countries *** MC Yes Novo Nordisk Long 7
Dornhorst et al. 36 2007 Cohort no (concurrent) 3330 (1665/1665) NR NR Adult Austria, Czech Republic and Denmark MC Yes Novo Nordisk Short 5
*

The value in brackets indicates (ni/nc) where, ni = the number of participants in the intervention group (glargine), and nc = the number of participants in the control group (detemir).

**

Czech Republic, United Kingdom, Republic of Ireland, Netherlands, Sweden and Finland.

***

Austria, Czech Republic, Denmark, Finland, Germany, Ireland, Israel, Netherlands, Sweden, Turkey and United Kingdom.

****

Studies with follow-up time up to 3 months were classified as short, 3–6 months as intermediate and >6 months as long.

NR, not reported; Cohort no, study with declaration of no conflict of interest; SC, single center; MC, multicenter.